A tennis and squash enthusiast is set to take part in the British Transplant Games in his home city, less than three years after he received a new liver. James Lawton from Oxford underwent a liver ...

The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...

Maxim raised the firm’s price target on Chemomab Therapeutics (CMMB) to $7 from $4 and keeps a Buy rating on the shares. The firm cites the ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

Tod Lashway had questions about his wife’s chronic disease and discovered he could possibly be the donor she desperately ...

They both joined us on Bridge Street this morning. Julianne was diagnosed with primary sclerosing cholangitis, or PSC, which is a rare, progressive liver disease. According to Hirschfield ...